Skip to main content
OpenTrials
Completed

NCT Number: NCT06213792

Visuo-Vestibular Adaptation in Virtual Reality

The vestibulo-ocular reflex (VOR) stabilizes the gaze during rapid head movements by inducing an eye rotation of equivalent amplitude but in the opposite direction to the head rotation. Normally, the ratio of eye rotation amplitude to head rotation, or VOR gain, is 1. Under some conditions such as growth or the use of corrective glasses, this gain is adapted to the new visuo-vestibular conditions. This well-known sensorimotor adaptation phenomenon can be achieved through the experimental creation of a conflict between vestibular and visual information.

Incremental velocity error (IVE) allows for a rapid adaption of the VOR at high speed by synchronously projecting a laser target that moves to create a progressively increasing visuo-vestibular conflict. However, this method does not correspond to the ecological conditions of VOR use, as the training is conducted in darkness and the visuo-vestibular conflict does not involve the entire visual scene.

Recreating this type of adaptation in a virtual reality environment could allow for adaptation with a visual stimulus involving the entire visual scene, thus more closely resembling the physiological conditions of VOR use. We hypothesize that a visual simulation of the entire scene would be more effective than an isolated target in VOR adaptation during high velocity head rotation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hôpital Neurologique

Bron, 69677, France

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age from 18 to 60
  • Understanding of the experimental instructions
  • Informed Consent

Exclusion criteria

  • Underlying ENT or neurological disorders
  • Corrected Visual Acuity lower than 5/10
  • Other conditions leading to oscillopsia or ataxia
  • Oculomotor palsy, ocular instability in primary position
  • Treatment that may affect ocular motility (psychotropes)
  • Cervical rachis pathology with instability
  • Cochlear Implants
  • Non-stabilized medical disease
  • Subject suffering from debilitating motion sickness or Virtual Reality sickness
  • Pregnant women
  • Patients under tutelage
  • Patient without social security

Treatment and study plan

Adaptation of the VOR

Other

Subjects will undergo adaptation of their VOR in virtual reality in two different conditions. The side on which the adaptation will take place and the type of condition with which the patients will start will be randomized. Subject will undergo passive rapid head movements done by an experienced examinator whilst fixing a target in front of them. The movement of the target relative to the movement of the head will increase every 90 seconds by 10% until the movement of the visual scene is twice that of the head movement. In one condition the visual scene will be only a target in a grey void. In the other condition the visual scene will be more complex and represent a target in the room in which the subject is seated. Subjects will undergo both conditions at least 7 days apart.

Primary outcomes

  1. VOR gain

    Time frame: 7 days

    VOR gain corresponds to the amplitude of the eye rotation devided by the amplitude of the head rotation for a given head impulse.

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: VIVRA

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Jan 19, 2024
Registry last updated
May 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.